Fc-Binding Unit for Homogeneous Site-Specific Antibody Conjugation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for conjugating target moieties to antibodies lack site-specific control, leading to inhomogeneous drug structures and impaired antibody function due to non-specific binding, which complicates the development of antibody-drug conjugates (ADCs) by affecting safety and reproducibility.

Innovation Solution

A compound comprising an Fc binding unit is developed to site-specifically transfer a reactive group to the Fc region of antibodies, using a novel structure that enhances reaction efficiency and plasma stability through a branched linker system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If random conjugation methods are used to attach target moieties to antibodies, then the conjugation process is simple, but the drug structure becomes inhomogeneous and antibody function is impaired

Engineering Contradiction:

Improveconjugation process simplicityVSAvoiddrug structure homogeneity

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent introduces a Fc binding unit as an intermediary molecule that mediates the conjugation process. This unit specifically binds to the Fc region of antibodies and transfers the target moiety to a controlled site, enabling site-specific conjugation while maintaining process feasibility. The intermediary facilitates precise positioning without requiring complex genetic modification or multiple purification steps.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If random conjugation methods are used, then the manufacturing process is straightforward, but the safety and reproducibility of ADCs are compromised

Engineering Contradiction:

Improvemanufacturing process simplicityVSAvoidADC safety and reproducibility

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent applies local quality by directing the conjugation to a specific local region (the Fc region) of the antibody rather than random attachment throughout the molecule. This localized approach ensures that the antigen-binding domains remain unaffected, maintaining antibody function and improving the reliability and reproducibility of the ADC product.

Inventive Principle:

Principle #3Local quality

3Manufacturing precision

If site-specific conjugation is achieved through genetic manipulation, then drug structure homogeneity is improved, but the device complexity and manufacturing difficulty increase

Engineering Contradiction:

Improvedrug structure homogeneityVSAvoidgenetic manipulation complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The Fc binding unit serves as a chemical intermediary that achieves site-specific conjugation without requiring genetic manipulation of the antibody. This approach maintains drug structure homogeneity while avoiding the complexity of genetic engineering, protein expression optimization, and cell line development associated with genetically modified antibodies.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250222123A1Compound comprising fc-binding unit, and conjugate prepared using same

Publication Date: 2025.07.10 ABTIS CO LTD

AI summary

Some embodiments of the present application provide a compound comprising Fc binding unit. The compound comprising Fc binding unit of the present application may be used to transfer a group of interest to an antibody in a position-specific manner. Furthermore, some embodiments of the present application provide a method for preparing an antibody conjugate comprising a group of interest (for example, a reactive group) using the compound comprising Fc binding unit.